Empowering Lives
Fighting Sickle Cell
Our Commitment To Hope
we are dedicated to making a positive impact in the lives of those living with sickle cell.
A Brief On Us
At the Mayowa Arikawe Foundation, our mission is rooted in the global awareness of sickle cell anemia. This inherited blood disorder affects millions of individuals worldwide, with over 300,000 babies born with sickle cell disease each year. We are committed to making a meaningful impact on the lives of those affected by this condition.
What Is Sickle Cell Disease?
Sickle cell disease is a genetic blood disorder that profoundly affects individuals and their families. It is caused by an inherited mutation in the hemoglobin gene, resulting in abnormal, “sickle-shaped” red blood cells.
Causes
Sickle cell disease is inherited when a person receives two abnormal hemoglobin genes, one from each parent, this genetic alteration leads to the production of rigid red blood cells that can obstruct blood vessels.
Impact
Sickle cell disease can cause chronic pain episodes, known as pain crises, along with anemia, fatigue, and susceptibility to infections, the condition can lead to organ damage and a range of health complications, impacting both physical and emotional well-being.
Our Plans To Fight The Disease
Donations
Through our ongoing commitment, we make donations to support individuals and organizations dedicated to the fight against sickle cell disease.
Awareness Events
We organize events, conferences, and workshops to share knowledge and experiences with communities, experts and patients
Patient Education
We provide resources and programs that empower patients and their families with the knowledge and tools they need to navigate the complexities of sickle cell disease
Research Funding
We fund critical projects and clinical trials that aim to improve treatments and find potential cures for sickle cell disease.
International Outreach
We work in collaboration with international organizations and governments to address the global impact of the disease
Advocacy
By raising our voices and collaborating with healthcare organizations, we aim to secure increased access to healthcare, early screening, and specialized treatment.
Learn more about sickle cell and how we can fight it
Our Plans To Fight The Disease
Donations
Through our ongoing commitment, we make donations to support individuals and organizations dedicated to the fight against sickle cell disease.
Patient Education
We provide resources and programs that empower patients and their families with the knowledge and tools they need to navigate the complexities of sickle cell disease
International Outreach
We work in collaboration with international organizations and governments to address the global impact of the disease
Awareness Events
We organize events, conferences, and workshops to share knowledge and experiences with communities, experts and patients
Research Funding
We fund critical projects and clinical trials that aim to improve treatments and find potential cures for sickle cell disease.
Advocacy
By raising our voices and collaborating with healthcare organizations, we aim to secure increased access to healthcare, early screening, and specialized treatment.
Learn more about sickle cell and how we can fight it
Spotlight Articles
UK approves gene-editing drug for sickle cell
The treatment for sickle cell disease and beta thalassemia is the first to be licensed using the gene-editing tool known as Crispr, for which its discoverers were awarded the Nobel prize in 2020.
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.
First Sickle Cell Gene Therapy Patient Leaves Hospital
“I thought I would have sickle cell for the rest of my life,” the 12-year-old Kendric Cromer, the first patient to receive a gene therapy for sickle cell since it was approved, said after 44 days in the hospital.
Spotlight Articles
UK approves gene-editing drug for sickle cell
The treatment for sickle cell disease and beta thalassemia is the first to be licensed using the gene-editing tool known as Crispr, for which its discoverers were awarded the Nobel prize in 2020.
FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease
Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older.
First Sickle Cell Gene Therapy Patient Leaves Hospital
“I thought I would have sickle cell for the rest of my life,” the 12-year-old Kendric Cromer, the first patient to receive a gene therapy for sickle cell since it was approved, said after 44 days in the hospital.
Join The Fight Today